Renal impairment INDEX

Lithium is used in the prophylaxis and treatment of mania and in the prophylaxis of bipolar disorders and recurrent depression. Lithium should be stopped 24 hours before major surgery but the normal dose can be continued for minor surgery, with careful monitoring of fluids and electrolytes. After major surgery, renal function is reduced and this may compromise clearance of lithium. Lithium is a drug with a narrow therapeutic index and it should be avoided if possible in patients with renal impairment. Renal function should be tested before initiating treatment. If lithium is given to patients with renal impairment, a reduced dose should be used and serum lithium concentrations should be monitored closely. 

In order to integrate further some of the various reactions mentioned, and to detect its presence by other methods, the vessels of the rat s mesoappendix were employed as a test object (Chambers-Zweifach preparation, 12). A good correlation between the presence of a vasoexcitor material-like substance in the extracts and the presence of hypertension was found. When the whole rat was used for assay, a much cruder index, sizable quantities of active pressor material were isolated from the blood only of those patients showing at least a degree of renal impairment (lessened ability to concentrate urine, etc.). In general it may be stated unequivocally that patients with severe hypertension have in their arterial blood extractable substances which are pressor for the rat there are less or undemonstrable amounts in blood of less severe or neurogenic hypertensive patients there is little or none in blood of normotensive subjects a vasoexcitor material-like activity is exerted by blood from most hypertensive patients adenyl compounds, having a depressor action, present in extracts of blood are less prevalent in those from hypertensive patients the active rat pressor material (pherentasin) is probably aminelike in nature, is not a protein, but may be a simple peptide or an amine. 

The serum uric acid concentration is an important index for clinical diagnosis of gout, leukemia, toxemia of pregnancy, and severe renal impairment. A number of enzymes are assayed in serum and urine for diagnostic purposes the more frequently used ones are discussed below. 

A retrospective cohort study observed an increased risk of renal impairment with the use of telavancin (33%). Predictors of renal impairment in this cohort of 21 patients included a high body mass index, previously recorded high trough levels of vancomycin and receipt of intravenous contrast dye prior to administration of telavancin [69 ]. 

While low serum cholesterol levels have been observed in malnourished patients, largely as a result of decreased synthesis of lipoproteins in the liver, hypocholesterolemia occurs later in the course of malnutrition and is therefore not useful as a screening test. PEM usually results in low serum urea nitrogen (BUN), urinary urea, and total nitrogen. Estimation of 24-h urine creatinine excretion is also a valuable biochemical index of muscle mass (when there is no impairment in renal function). The urinary CHI is correlated to lean body mass and anthropometric measurements. In edematous patients, for whom the extracellular fluids contribute to body weight and spuriously high body mass index values, the decreased CHI values are especially useful in diagnosing malnutrition. 

Lithium salts have a narrow therapeutic index. Lithium levels should be monitored every 3 months. The long-term use of lithium is associated with thyroid disorders and mild cognitive and memory impairment. Thyroid and renal functions should be checked every 6-12 months,... 

Sirolimus is a substrate and inhibitor of CYP3A4 with a narrow therapeutic index and is associated with cognitive impairment and nephrotoxicity. There is a synergistic effect when it is co-administered with ciclosporin, possibly because both are substrates of CYP3A4 (and thus compete at metabolic sites) and are P-gp substrates that may competitively inhibit each other at the efflux pump. There is considerable interindividual variability, with a 10-fold range in plasma concentration in renal transplant recipients when it is given at a dosage of 5 mg per day. 

Free pyridoxal either leaves the cells or is oxidized to 4-pyridoxic acid by aldehyde dehydrogenase (which is present in all tissues) and also by hepatic and renal aldehyde oxidases. 4-Pyridoxic acid is actively secreted by the renal tubules, so measurement of the plasma concentration provides an index of renal function (Coburn et al., 2002). There is some evidence that oxidation to 4-pyridoxic acid increases with increasing age in elderly people, the plasma concentration of pyridoxal phosphate is lower, and that of 4-pyridoxic acid higher, than in younger subjects even when there is no evidence of impaired renal function (Bates et al., 1999b). Small amounts of pyridoxal and pyridox-amine are also excreted in the urine, although much of the active vitamin Be that is filtered in the glomerulus is reabsorbed in the kidney tubules. 

CDER, CBER. Pharmacokinetics in patients with impaired renal hmction — study design, data analysis, and impact on dosing and labeling. Guidance for Industry, Rockville FDA 1998. (Internet at http //www.fda.gov/cder/guidance/index.htm.)... 

Test results are affected by defective intestinal absorption caused by intestinal disease or variations in transit time, by impaired hepatic conjugation caused by liver disease, and by impaired renal excretion. To compensate for these possible errors, a control substance (e.g., PABA) may be given on a second day, or alternatively, C-PABA or p-aminosalicylic acid (PAS) can be given orally with the NBT-PABA. Low recovery of the control substance in the urine indicates probable decreased intestinal absorption or decreased renal excretion. About 60% (range 48% to 72%) of the orally administered dose is recovered in the urine normally. In pancreatic insufficiency, PABA excretion is significantly decreased. The result is then calculated as a pancreatic excretion index (PEI) as follows ... 

United States Food and Drug Administration. 1998. Guidance for Industry Pharmacokinetics in Patients With Impaired Renal Function Study Design, Data Analysis and Impact on Dosing and Labeling. US Dept Flealth and Fluman Services Washington accessed March 16, 2005, from http //www.fda.gov/cder/guidance/index.htm. 

Although venlafaxine is a weak inhibitor of CYP2D6, variability has been observed in the pharmacokinetic parameters of venlafaxine in patients with hepatic or renal function impairment. As a precaution, elderly patients taking venlafaxine concurrently with a drug that has a narrow therapeutic index and also is metabolized by CYP2D6 should be carefully monitored. Concurrent use of CYP3A4 inhibitors with venlafaxine has been shown to interfere with its metabolism and clearance. Similar to the other antidepressants that block 5-HT reuptake, venlafaxine may interact pharmacodynamically to cause toxic levels of 5-HT to accumulate, leading to the 5-HT syndrome. 

Experiments in animals have found that proliferation of vascular smooth muscle cells can be inhibited by calcitriol administration (Mitsuhashi et al. 1991). An over-active renin-angiotensin system (RAS) can impair renal function and deteriorate cardiovascular health (Li 2012), and down-regulation of RAS activity is one of the key mechanisms proposed for calcitriol (Li et al. 2002). Evidence to support this mechanism has been primarily obtained from animal experiments for example, treatment with calcitriol has been shown to down-regulate RAS and to improve cardiac function in la-hydroxylase knockout mice (Zhou et al. 2008), and in salt-sensitive rats with cardiac hypertrophy (Bae et al. 2011, Choi et al. 2011). However, a recent randomized controlled trial in patients with chronic kidney disease did not find improvements in left ventricular mass index or diastolic function by treatment with paricalcitol (active vitamin D analogue) (Thadhani et al. 2012). 

---